Moderna, Inc. (MRNA)
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
Moderna is right in the middle: the good and the not-so-good roughly cancel out.
- What's working
- The stock has been climbing and sits near the top of its range for the year.
- Worth watching
- It keeps less of each dollar it brings in than most other healthcare companies.
Analyst price target
~12-month · 18 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About Moderna, Inc.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally…
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4,700
- Headquarters
- Cambridge, MA
Similar stocks
What’s behind the score
Valuation
P/B 12.9 — lower than 14% of Healthcare peers
P/S 39.1 — lower than 0% of Healthcare peers
EV/EBITDA -37.9 — lower than 97% of Healthcare peers
EV/Revenue 37.3 — lower than 0% of Healthcare peers
FCF yield 0.3% — higher than 3% of Healthcare peers
Profitability & quality
Gross margin -66.0% — higher than 3% of Healthcare peers
Operating margin -557.9% — higher than 3% of Healthcare peers
Net margin -141.4% — higher than 3% of Healthcare peers
ROE -39.0% — higher than 4% of Healthcare peers
ROA -13.3% — higher than 3% of Healthcare peers
Financial health
Debt/equity 0.2 — lower than 85% of Healthcare peers
Current ratio 2.29 — higher than 86% of Healthcare peers
Quick ratio 2.07 — higher than 86% of Healthcare peers
Cash/debt 3.99 — higher than 97% of Healthcare peers
Debt/EBITDA -0.59 — lower than 100% of Healthcare peers
Growth
Revenue growth 2.1% YoY — higher than 10% of Healthcare peers
Ownership & investor activity
Payout ratio 0.0% — somewhat unusual vs Healthcare peers
Net insider buying, +1.6% of insider shares
Institutions net sold, -13.8% of shares held
Insiders hold 7.3% of shares outstanding
9.4% of float sold short
Momentum
Above its 50- & 200-day averages
89% of the way from its 52-week low to high